

13th Annual



WPC






World Pharma Congress

Tackling Translational Challenges





May 21-23, 2014 | Westin Boston Waterfront, Boston, MA



May 21-22

-  Tumor Models for Targeted Therapy
-  Imaging in Oncology
-  Preclinical Drug Safety
-  Formulation & Drug Delivery
-  Targeting Pain

May 22-23

-  Tumor Models for Cancer Immunotherapy
-  *In vitro* Tumor Models
-  Epigenetics Screening
-  Efficient Process Chemistry

Keynote Speaker:



Catalyzing
Translational
Innovation

Christopher P. Austin, M.D.
*Director, National Center for
Advancing Translational Sciences,
National Institutes of Health*

Conference Highlights

- 90+ presentations led by industry experts focusing on preclinical efforts targeted towards drug discovery/delivery, screening, safety and process chemistry
- 450+ International Attendees
- Five Pre-Conference Short Courses
- Expansive Exhibit Hall – 40+ Sponsors & Exhibitors
- Dedicated Poster Viewing, Roundtables and Panel Discussions

PREMIER
SPONSOR



**The Jackson
Laboratory**

*Leading the search
for tomorrow's cures*

Clinically validated screening of compounds in patient samples for efficacy & hematotoxicity

Joan Ballesteros, CSO Vivia Biotech

We screen 2.000 compounds/patient sample in hematological malignancies for 2^{ry} screening and pharmacological characterization, searching best drug combinations. We measure depletion tumor cells, proliferation, differentiation, and epigenetics using whole patient samples. Validated >80% correlation in 1st line AML. A novel Hematotoxicity assay measures depletion of hematopoietic precursors including solid cancers.